<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489333</url>
  </required_header>
  <id_info>
    <org_study_id>H-0001-01</org_study_id>
    <secondary_id>087/2006</secondary_id>
    <nct_id>NCT00489333</nct_id>
  </id_info>
  <brief_title>ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome</brief_title>
  <official_title>The Effects of ProAlgaZyme Novel Algae Infusion vs. Placebo on Metabolic Syndrome and Markers of Cardiovascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Enhancement Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Yaounde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Enhancement Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of supplementation with ProAlgaZyme (a&#xD;
      novel fermentation product of a freshwater algae ecosystem) vs. placebo on Metabolic Syndrome&#xD;
      and indicators of cardiovascular health including: body weight and fat, blood lipids,&#xD;
      inflammatory markers such as hsCRP, blood pressure and fasting blood glucose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome, a set of symptoms strongly associated with increased risk for both&#xD;
      cardiovascular disease and diabetes, is generally linked to obesity and has become a serious&#xD;
      problem in many industrialized countries. Agents that aid in weight loss or help to normalize&#xD;
      blood lipids or inflammation may reduce the risk of metabolic syndrome and therefore, reduce&#xD;
      the risk of cardiovascular disease and diabetes. This study is a single-center, double-blind,&#xD;
      placebo-controlled, parallel design, to evaluate the effects of ProAlgaZyme (4 fl. oz. daily)&#xD;
      on metabolic syndrome and markers of cardiovascular health including blood lipids,&#xD;
      inflammatory markers and anthropometric measurements.&#xD;
&#xD;
      Comparisons: ProAlgaZyme vs. placebo [Time frame: 10 weeks]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hsCRP</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipids (total cholesterol, triglycerides HDL-C, LDL-C)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric measurements (weight/BMI, % body fat, blood pressure)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RBC Sedimentation Rate</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ProAlgaZyme</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must meet 3 of the following criteria:&#xD;
&#xD;
               -  BMI â‰¥30 kg/m2&#xD;
&#xD;
               -  HDL Cholesterol of &lt;40&#xD;
&#xD;
               -  Triglycerides &gt;150 mg/dl&#xD;
&#xD;
               -  Fasting blood glucose &gt;100 mg/dl&#xD;
&#xD;
               -  Blood pressure &gt;130/85 mm Hg&#xD;
&#xD;
               -  Total Cholesterol of &gt;200 mg/dl&#xD;
&#xD;
               -  LDL Cholesterol of &gt;160 mg/dl&#xD;
&#xD;
               -  Interleukin 6 (IL-6) &gt;5pg/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Morbidly obese: BMI &gt;40 kg/m2&#xD;
&#xD;
          -  Taking any cholesterol-lowering medications 30 days prior to the start of enrollment&#xD;
             and during the course of the study.&#xD;
&#xD;
          -  Enrolled in another clinical study in the past 6 months.&#xD;
&#xD;
          -  Pregnant, actively infected, on medication that interfered with healing (for example,&#xD;
             steroids), were inflicted with systemic disease such as AIDS, HIV, active hepatitis or&#xD;
             active malignancy (clinical signs within the past 5 years), or suffered from diabetes&#xD;
             mellitus requiring daily insulin management.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julius Oben, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>June 19, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>June 19, 2007</last_update_submitted>
  <last_update_submitted_qc>June 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2007</last_update_posted>
  <keyword>ProAlgaZyme</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>hsCRP</keyword>
  <keyword>Lipids</keyword>
  <keyword>Algae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

